SCHEMBL174911

SCHEMBL174911

CCCc1ccc[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DAO P14920 2/20 0.43
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
INCENP Q9NQS7 1/20 0.43
MCL1 Q07820 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
EPHX2 P34913 1/20 0.39
ALDH1A1 P00352 3/20 0.37
PARP1 P09874 1/20 0.37
RAB9A P51151 1/20 0.35
GPR84 Q9NQS5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10692239 0.88 DAO (0.41) KDM4EGAAMEN1POLBMAPT
SCHEMBL2495417 0.86 GPR84 (0.46) KDM4EGAATHRBDAOAURKA
SCHEMBL27397512 0.85 GPR84 (0.49) KDM4ETHRBMCL1ALDH1A1GPR84
SCHEMBL10767574 0.85 GPR84 (0.49) KDM4ETHRBMCL1ALDH1A1GPR84
SCHEMBL14974903 0.85 GPR84 (0.49) KDM4ETHRBMCL1ALDH1A1GPR84
SCHEMBL28243243 0.85 GPR84 (0.49) KDM4ETHRBMCL1ALDH1A1GPR84
SCHEMBL10764266 0.85 GPR84 (0.49) KDM4ETHRBMCL1ALDH1A1GPR84
SCHEMBL5166986 0.85 GPR84 (0.49) KDM4ETHRBMCL1ALDH1A1GPR84
SCHEMBL797191 0.85
SCHEMBL9234355 0.81 DAO (0.45) KDM4EGAAMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0093498-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING N-SUBSTITUTED-3-HYDROXYPYRID-2-ONE OR -4-ONE DERIVATIVES NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1986-11-26 EP claimed
EP-4248972-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 EP disclosed
CN-111542557-B Conjugated diene rubber 日本瑞翁株式会社 2023-03-28 CN disclosed
CN-111868098-B Method for producing conjugated diene rubber 日本瑞翁株式会社 2022-12-23 CN disclosed
CN-115348975-A Conjugated diene polymer, method for producing conjugated diene polymer, conjugated diene polymer composition, and rubber composition 旭化成株式会社 2022-11-15 CN disclosed
CN-114933676-A Polyfunctional vinyl aromatic copolymer and process for producing the same, conjugated diene copolymer and composition thereof, crosslinked product, and tire member 日铁化学材料株式会社 2022-08-23 CN disclosed
CN-110325556-B Modified conjugated diene polymer, polymer composition, and rubber composition 旭化成株式会社 2022-05-13 CN disclosed
CN-110857344-B Modified conjugated diene polymer composition, rubber composition, and method for producing rubber composition 旭化成株式会社 2022-04-15 CN disclosed
CN-110862590-B Modified conjugated diene polymer composition, rubber composition, and method for producing rubber composition 旭化成株式会社 2022-04-12 CN disclosed
CN-110878151-B Rubber composition 旭化成株式会社 2022-04-12 CN disclosed
WO-2012028676-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-08 WO disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
EP-2167499-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Schering Pharma AG (DE) 2010-03-31 EP disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed
EP-0375133-A1 Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX KDM4E 2573/4885GAA 833/4885MEN1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.